Enoch Kariuki

Enoch Kariuki has held a variety of roles in the healthcare and biopharmaceutical industries. In 2008, they began their career as a Post-Doctoral Fellow in R&D Strategy and Analytics at Bristol-Myers Squibb. In 2011, they moved to UBS as an Associate Director in the Global Healthcare Group, where they executed multiple equity, debt, and advisory transactions. In 2013, they joined Leerink Partners LLC as a Senior Associate in Healthcare Investment Banking, and was involved in executing multiple IPOs, Follow-on Offerings, and M&A transactions. In 2014, they became a Vice President at H.I.G. BioHealth Partners, where they were a member of the investment team. In 2018, they joined Synthorx Inc. as Senior Vice President of Corporate Development. In 2020, they became the Chief Financial Officer at VelosBio Inc., which was later acquired by Merck for $2.75 billion. In 2021, they became the Board Director and Audit Chair for both Zentalis Pharmaceuticals and Imago BioSciences. Enoch currently serves as Chief Executive Officer of Lengo Therapeutics, which was acquired by Blueprint Medicines for up to $465 million, and is a Member of the Dean's MBA Council at The Tuck School of Business at Dartmouth.

Enoch Kariuki's education history includes a Doctor of Pharmacy from Texas Southern University (2001-2008), a Diploma in Computer Electronics and Engineering from Graffins College - Nairobi (2000), and a KCSE from Alliance High School (1996-1999). Enoch also completed an MBA from The Tuck School of Business at Dartmouth (2009-2011) and a Tuck International Exchange Program from the Indian School of Business (2010) in Finance & Strategy.